KARE Biosciences

Executive Summary

KARE Biosciences is a San Diego-based biotechnology company focused on repurposing existing drugs and developing nutritional supplements for metabolic and cardiovascular diseases. Founded in 2018, the company's lead program involves repurposing ramatroban, a thromboxane receptor antagonist originally used for allergic rhinitis, for multiple indications including metabolic and cardiovascular conditions. Ramatroban is currently in Phase 3 trials, leveraging its known safety profile to accelerate development. Additionally, KARE is developing a specialized multivitamin for kidney patients to address nutritional deficiencies common in chronic kidney disease. The company's repurposing strategy reduces development risk and costs, but the clinical efficacy of ramatroban in new indications remains unproven, and the multivitamin market is competitive. With a lean pipeline and limited financial disclosure, KARE represents a speculative investment opportunity contingent on positive Phase 3 data and successful commercialization.

Upcoming Catalysts (preview)

• H2 2026Phase 3 topline data for ramatroban in metabolic indication50% success
• Q2 2026FDA clearance or GRAS notification for kidney multivitamin70% success